Stocks股票 / Health Care / DXCM
DXCM US listed · USD美股 · 美元
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management.德康医疗公司是一家美国跨国医疗保健公司,开发、制造、生产并分销用于糖尿病管理的连续血糖监测系统。
Company news公司新闻
The latest reporting最新报道
One story, with the reporting behind it.将同一事件汇总,保留各来源报道。
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考;使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动,请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-10-31Earnings财务业绩
Estimates being cut预期下调
Beat expectations 4 quarters in a row连续 4 季度超预期
Post-earnings drift: +3.8% (20d)财报后漂移:+3.8%(20日)
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度(近几个季度) · average平均 11.4%
Valuation估值
Roughly fair vs sector相对行业估值合理| Multiple指标 | DXCM | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(历史) | 37.86x | 31.94 | |
| P/B市净率 | 11.53x | 3.53 | |
| P/S市销率 | 6.79x | 3.11 | |
| Earnings yield盈利收益率 | 2.64% | 2.41 | |
| FCF yield自由现金流收益率 | 3.40% | 4.00 | |
| Shareholder yield股东收益率 | 1.58% | 1.88 | |
| EV/EBITDA企业价值/EBITDA | 26.42x | 19.31 | |
| P/FCF市值/自由现金流 | 29.40x | 22.99 |
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Debt coming due到期债务
FY2015 10-KIn the 12-month bucket following fiscal period end 2015-12-31, it reported $2.3M due — about 100% of its disclosed principal.在财年期末 2015-12-31 之后12个月的区间内,已披露到期本金为 $2.3M,约占其披露本金的 100%。
All maturity buckets are measured from fiscal period end 2015-12-31, not from today.所有到期区间均从财年期末 2015-12-31 起算,而非从今天起算。
Cash reported at 2025-12-31: $917700000.截至 2025-12-31 披露的现金:$917700000。 Operating cash flow exceeded or equaled equipment spending over 2025-01-01 to 2025-12-31; no cash burn to measure.在 2025-01-01 至 2025-12-31 期间,经营现金流不低于设备支出,无可衡量的现金消耗。
Capital-need coverage is partial; incomplete or incompatible filing inputs are not combined.资本需求覆盖信息不完整;不会合并不完整或不兼容的报告数据。
Any available cash-flow scenario is context only. Missing or incompatible inputs are not replaced with zero or a financing forecast.可用现金流情景仅供参考;缺失或不兼容的输入不以零值或融资预测替代。
Sources and cash-flow calculation来源与现金流计算
Figures are XBRL facts from one filing — no two years are mixed. Filing数据取自同一份文件中的 XBRL 事实,不跨文件拼接。文件
0001093557-16-000432, period ending报告期截至 2015-12-31, unit单位 USD.
Cache acquired缓存获取时间: 2026-10-26T08:09:58.656540+00:00.
1/6 buckets reported.个区间有披露。
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive— absentLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive— absent
Annual period年度区间 2025-01-01 — 2025-12-31 · USD · 10-K · 0001093557-26-000027 · Filed提交日期 2026-02-12.
Cache acquired缓存获取时间: 2026-10-26T08:09:58.656540+00:00 · Evaluated as of评估截至 2026-10-31.
- Reported operating cash flow已披露经营活动现金流: $1440700000
- Reported equipment spending (capex outflow)已披露设备支出(资本开支流出): $363500000
- Derived free cash flow (operating cash flow minus capex)计算所得自由现金流(经营现金流减资本开支): $1077200000
Cash is the reported balance at period end. The runway scenario holds this annual cash-flow pace constant and excludes debt payments, restricted-cash adjustments and future financing.现金为期末已披露余额。现金跑道情景假设本年度现金流速度保持不变,不包括债务偿还、受限现金调整与未来融资。
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Options positioning期权持仓
as of last close截至上一收盘Market makers are net long gamma — price pinned near current level做市商净持有正伽玛,价格倾向于在当前水平附近震荡
Flow:资金流向: $2M premium traded; 0% 0DTE; 8 fresh positions; P/C 2.45; ~leans bullish (direction approx)成交权利金 $2M;0DTE占0%;8个新建仓;看跌看涨比 2.45;≈偏看涨(方向近似)
Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向: -$12.0M net (0 buyers, 8 sellers)-$12.0M 净值(0 买家,8 卖家)
Signal history信号历史
engine events引擎事件Company profile公司档案
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management.德康医疗公司是一家美国跨国医疗保健公司,开发、制造、生产并分销用于糖尿病管理的连续血糖监测系统。
- Margin compression despite revenue growth
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(静态) | 37.9× | 31.9× | 40% |
| Price / Book市净率 | 11.5× | 3.5× | 10% |
| Price / Sales市销率 | 6.8× | 3.1× | 25% |
| EV / EBITDAEV/EBITDA | 26.4× | 19.3× | 33% |
| Earnings yield盈利收益率 | 2.6% | 2.4% | 55% |
| Free-cash-flow yield自由现金流收益率 | 4.5% | 5.2% | 42% |
| Shareholder yield股东综合回报率 | 1.6% | 1.9% | 45% |
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | +5.6% | -0.6% |
| 1 Month近1月 | -4.6% | -0.9% |
| 3 Months近3月 | -1.4% | +1.4% |
| 6 Months近6月 | +34.1% | +5.4% |
| Year to date年初至今 | +23.7% | +11.5% |
| 1 Year近1年 | +20.7% | +12.4% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $1.9B | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| EPS每股收益 | $5.06 | $1.55 | $0.82 | $1.30 | $1.42 | $2.09 |
| Free cash flow自由现金流 | $277M | $53M | $305M | $512M | $631M | $1.1B |
| Gross margin毛利率 | 66.4% | 68.6% | 64.7% | 63.2% | 60.5% | 60.1% |
| Net margin净利率 | 25.6% | 6.3% | 11.7% | 14.9% | 14.3% | 17.9% |
| FCF margin自由现金流利润率 | 14.4% | 2.2% | 10.5% | 14.1% | 15.6% | 23.1% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: earnings cash-backed盈利质量:盈利有现金支撑
- Working capital: inventory +168% vs sales +142%; receivables +184% vs sales +142% — demand & revenue-quality risk营运资本:存货 +168% 对销售 +142%;应收 +184% 对销售 +142%——需求与营收质量风险
- Pricing power: gross margin −6.3pts over 6 years定价能力:毛利率 6 年下降 6.3 个百分点
- Capital discipline: share count +300.4% over 6 years (dilution)资本纪律:股本 6 年增加 300.4%(稀释)
- Balance sheet: Altman Z 7.39 — safe zone资产负债表:Altman Z 7.39——安全区
Indicator readings指标读数
Timeframe alignment多周期共振
Volatility regime波动状态
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Jun 2026 | $0.70 | $0.61 | +14.8% |
| Mar 2026 | $0.56 | $0.47 | +19.1% |
| Dec 2025 | $0.68 | $0.65 | +4.6% |
| Sep 2025 | $0.61 | $0.57 | +7.0% |